Monday March 16, 2026
This week’s signal: neurovascular innovation is accelerating, and the pressure for commercialization readiness is rising — as acquisitions, new funding for robotic stroke technologies, and regulatory milestones shape how the next generation of devices reaches patients.
Also, a quick thank you to Kelvyn Cullimore, President & CEO of BioUtah (former CEO at Dynatronics), for hosting an outstanding life sciences event in Salt Lake City last week and including us in the conversation. The energy around Utah’s medtech ecosystem was unmistakable.
LSI USA ‘26 Emerging Medtech Conference begins today in Dana Point, CA, USA.
8 things to watch this week:
1. 🧠 Medtronic Expands Neurovascular Portfolio With Scientia Acquisition
Medtronic is expanding its neurovascular capabilities through the acquisition of Scientia Vascular, signaling continued consolidation around stroke and neurovascular intervention technologies. The move reinforces how strategic acquisitions remain one of the fastest paths for large strategics to strengthen highly specialized portfolios.
Today’s Medical Developments
2. 💰 Vitestro Raises $70M to Advance Autonomous Blood Draw Technology
Vitestro secured $70 million to accelerate development of its autonomous blood-draw platform, aiming to address workforce shortages and streamline diagnostics workflows. Automation at the point of care is becoming one of the most compelling investment themes across health systems.
Ventureburn
3. 🧠 xCATH Secures $30M Series C to Improve Global Outcomes in Neurovascular Care
xCATH raised $30 million to expand its robotic catheter technology designed for remote stroke intervention. The funding reflects growing interest in robotic endovascular procedures that could enable specialists to treat patients across geographic boundaries.
Zawya
4. 🔎 Before You Raise, Launch, or Scale — Know If You’re Actually Ready
Medical device companies rarely fail because the technology doesn’t work.
They fail because commercialization, reimbursement, and adoption strategy weren’t aligned early enough. RŌG Health helps medtech leaders assess whether their company is truly ready for key milestones such as FDA clearance, fundraising, and market launch.
Take our 1-minute readiness check to see where your strategy stands — and discover the engagement path designed for your stage. →
Sponsored
5. 🧾 QT Imaging Achieves Major Reimbursement Milestone With AMA Category III CPT Code for 3D Breast Imaging
QT Imaging secured a Category III CPT code for its 3D breast imaging technology — an important step toward broader reimbursement and clinical adoption. For emerging device companies, coding milestones often mark the transition from technical validation to scalable commercialization.
Nasdaq
6. 👁️ FDA Approves TECNIS PureSee IOL for Cataract Patients
Johnson & Johnson’s TECNIS PureSee intraocular lens received FDA approval, adding another option in the rapidly evolving premium cataract lens market. Incremental optical performance improvements continue to drive competition in one of ophthalmology’s most commercially mature segments.
Eyes On Eyecare
7. 🖥️ GE Healthcare Imaging Viewer Granted FDA Clearance
GE Healthcare received FDA clearance for a new imaging viewer designed to enhance visualization and workflow for clinicians reviewing diagnostic scans. Software-enabled imaging tools are becoming increasingly central to clinical decision-making and hospital efficiency.
ITN Online
8. ⚖️ FDA Finalizes Guidance on Weight-Loss Devices
The FDA finalized guidance outlining regulatory expectations for weight-loss devices, providing greater clarity for developers navigating obesity-related indications. With the rapid growth of GLP-1 drugs, the device side of metabolic health is likely to evolve quickly alongside pharmaceutical treatments.
RAPS
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.